30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

4Q13/2013 Revenue: Stryker

4Q13 revenue: $2,468MM, +6% (U.S. $1,636MM, +7%; ex-U.S. $832MM, +8%)

Recon $1,107MM, +8% (U.S. +9%, ex-U.S. +7%)

  • Hips $341MM, +8% (U.S. +10%, ex-U.S. +6%)
  • Knees $371MM, +5% (U.S. +8%, ex-U.S. -2%)
  • Trauma/Extremities $307MM, +12% (U.S. +8%, ex-U.S. +17%; U.S. Foot/Ankle +36%)

 

*MedSurg $924MM, +7% (U.S. +6%, ex-U.S. +7%)

  • Endoscopy $336MM, +10% (U.S. +12%, ex-U.S. +7%)

 

Neurotechnology/Spine $437MM, +8% (U.S. +5%, ex-U.S. +13%)

  • Neurotechnology $240MM, +10% (U.S. +7%, ex-U.S. +14%)
  • Spine $197MM, +5% (U.S. +2%, ex-U.S. +12%)

 

  • AAOS showcase will include new products that are largely incremental across various segments
  • Planning initial launch of reverse shoulder by 2Q, with full launch in late 2Q/early 3Q

 

Following highlights pertain to 4Q.

  • Ex-U.S. knees continued to feel impact of disruption to Asia distribution reported in 3Q13; expected to return to more normalized growth by end of 1Q14
  • Closed acquisition of MAKO Surgical: slated to commence trial for total knee software in 1H14
  • Claims close to 20% market share in uni knee segment with MAKO acquisition
  • All sales for MAKO will be reported under orthopaedics, with a separate capital group selling robotics
  • Trauma sales continue to be led by new products, sales execution, strong foot/ankle sales
  • Bulk of extremity sales growth arising from market expansion: new physicians performing procedures in which they previously used K-wires, etc.
  • Interventional spine led with “strong double-digit sales growth”

 

2013 revenue: $9,021MM, +4% (U.S. $5,984MM, +6%; ex-U.S. $3,037MM, +6%)

Recon $4,004MM, +7% (U.S. +8%, ex-U.S. +6%)

  • Hips $1,272MM, +6% (U.S. +7%, ex-U.S. +5%)
  • Knees $1,371MM, +3% (U.S. +3%, ex-U.S. +1%)
  • Trauma/Extremities $1,116MM, +15% (U.S. +18%, ex-U.S. +12%)

 

*MedSurg Equipment $3,359MM, +4% (U.S. +4%, ex-U.S. +4%)

  • Endoscopy $1,167MM, +6% (U.S. +7%, ex-U.S. +5%)

 

Neurotechnology/Spine $1,658MM, +8% (U.S. +6%, ex-U.S. +10%)

  • Neurotechnology $915MM, +11% (U.S. +11%, ex-U.S. +12%)
  • Spine $743MM, +3% (U.S. +2%, ex-U.S. +7%)

*MedSurg includes patient handling and emergency medical equipment.